Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease

Neurobiology of Aging

Volumn 31, Issue 10, 2010, Pages 1743-1757

  Dorfman, Verónica Berta ^a   Pasquini, Laura ^b   Riudavets, Miguel ^c   López Costa, Juan José ^b   Villegas, Andrés ^d   Troncoso, Juan Carlos ^e   Lopera, Francisco ^d   Castaño, Eduardo Miguel ^a   Morelli, Laura ^a  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c FLENI   (Argentina)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Astrocytes; Human brain; Insulin degrading enzyme; Neprilysin; Presenilin

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PRESENILIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME CONFORMATION; FAMILIAL DISEASE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MICROGLIA; MISSENSE MUTATION; NEURITE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SENILE PLAQUE; VASCULAR AMYLOIDOSIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASTROCYTES; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL CORTEX; FEMALE; HUMANS; INSULYSIN; MALE; MICROGLIA; MIDDLE AGED; NEPRILYSIN; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; PROTEIN CONFORMATION;

EID: 77955846215     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.09.016     Document Type: Article

References (56)

1. Akiyama H., Kondo H., Ikeda K., Kato M., McGeer P.L. Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res. 2001, 902:277-281.
2. Apelt J., Ach K., Schliebs R. Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci. Lett. 2003, 339:183-186.
3. Bernstein H.G., Ansorge S., Riederer P., Reiser M., Frölich L., Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci. Lett. 1999, 263:161-164.
4. Box G.E.P., Cox D.R. An analysis of transformations (with discussion). J. R. Stat. Soc. B 1964, 26:211-252.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
6. Brun A., Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 1986, 19:253-262.
7. Caccamo A., Oddo S., Sugarman M.C., Akbari Y., LaFerla F.M. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol. Aging 2005, 26:645-654.
8. Castaño E.M., Prelli F., Soto C., Beavis R., Matsubara E., Shoji M., Frangione B. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J. Biol. Chem. 1996, 271:32185-32191.
9. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.W., Kovacina K.S., Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 2003, 162:313-319.
10. Cullen K.M., Kócsi Z., Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol. Aging 2006, 27:1786-1796.
11. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390.
12. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F., Pasquier F., David J.P. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002, 59:398-407.
13. Dewachter I., Van Dorpe J., Smeijers L., Gilis M., Kuiperi C., Laenen I., Caluwaerts N., Moechars D., Checler F., Vanderstichele H., Van Leuven F. Aging increased amyloid β peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin 1. J. Neurosci. 2000, 20:6452-6458.
14. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid betaprotein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4162-4167.
15. Fukami S., Watanabe K., Iwata N., Haraoka J., Lu B., Gerard N.P., Gerard C., Fraser P., Westaway D., St George-Hyslop P., Saido T.C. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci. Res. 2002, 43:39-56.
16. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos L., Younkin L.H., Suzuki N., Younkin S.G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 1995, 270:7013-7016.
17. Güntert A., Döbeli H., Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006, 143:461-475.
18. Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 2001, 24:S45-48.
19. Hartman R.E., Laurer H., Longhi L., Bales K.R., Paul S.M., McIntosh T.K., Holtzman D.M. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J. Neurosci. 2002, 22:10083-10087.
20. Haass C., De Strooper B. The presenilins in Alzheimer's disease-proteolysis holds the key. Science 1999, 286:916-919.
21. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., Saido T.C. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292:1550-1552.
22. Jellinger K.A. Vascular-ischemic dementia: an update. J. Neural. Transm. Suppl. 2002, 62:1-23.
23. Jeynes B., Provias J. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathol. 2006, 112:417-427.
24. Kalback W., Watson M.D., Kokjohn T.A., Kuo Y.M., Weiss N., Luehrs D.C., Lopez J., Brune D., Sisodia S.S., Staufenbiel M., Emmerling M., Roher A.E. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 2002, 41:922-928.
25. Kim M., Hersh L.B., Leissring M.A., Ingelsson M., Matsui T., Farris W., Lu A., Hyman B.T., Selkoe D.J., Bertram L., Tanzi R.E. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J. Biol. Chem. 2007, 282:7825-7832.
26. Kuo W.L., Gehm B.D., Rosner M.R., Li W., Keller G. Inducible expression and cellular localization of insulin-degrading enzyme in a stably transfected cell line. J. Biol. Chem. 1994, 269:22599-22606.
27. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., Kalback W.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Roher A.E. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001, 276:12991-12998.
28. Leal M.C., Dorfman V.B., Gamba A.F., Frangione B., Wisniewski T., Castaño E.M., Sigurdsson E.M., Morelli L. Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J. Neuropathol. Exp. Neurol. 2006, 65:976-987.
29. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
30. Lemere C.A., Lopera F., Kosik K.S., Lendon C.L., Ossa J., Saido T.C., Yamaguchi H., Ruiz A., Martinez A., Madrigal L., Hincapie L., Arango J.C., Anthony D.C., Koo E.H., Goate A.M., Selkoe D.J., Arango J.C. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 1996, 2:1146-1150.
31. Levy E., Carman M.D., Fernandez-Madrid I., Power M.D., Lieberburg I., van Duinen S.G., Bots G.T.A.M., Luyendijk W., Frangione B. Science 1990, 248:1124-1126.
32. Liu K., Solano I., Mann D., Lemere C., Mercken M., Trojanowski J.Q., Lee V.M. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol. 2006, 112:163-174.
33. Maurer K., Hoyer S. Alois Alzheimer revisited: differences in origin of the disease carrying his name. J. Neural. Transm. 2006, 113:1645-1658.
34. Miners J.S., Van Helmond Z., Chalmers K., Wilcock G., Love S., Kehoe P.G. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 2006, 65:1012-1021.
35. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
36. Morelli L., Llovera R., Gonzalez S.A., Affranchino J.L., Prelli F., Frangione B., Ghiso J., Castano E.M. Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem. 2003, 278:23221-23226.
37. Morelli L., Llovera R.E., Mathov I., Lue L.F., Frangione B., Ghiso J., Castaño E.M. Insulin degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. Biol. Chem. 2004, 279:56004-56013.
38. Pappolla M.A., Bryant-Thomas T.K., Herbert D., Pacheco J., Fabra Garcia M., Manjon M., Girones X., Henry T.L., Matsubara E., Zambon D., Wolozin B., Sano M., Cruz-Sanchez F.F., Thal L.J., Petanceska S.S., Refolo L.M. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61:199-205.
39. Perez A., Morelli L., Cresto J.C., Castaño E.M. Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 2000, 25:247-255.
40. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging 2005, 26:355-361.
41. Roher A.E., Lowenson J.D., Clarke S., Woods A.S., Cotter R.J., Gowing E., Ball M.J. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:10836-10840.
42. Roher A.E., Kuo Y.M., Esh C., Knebel C., Weiss N., Kalback W., Luehrs D.C., Childress J.L., Beach T.G., Weller R.O., Kokjohn T.A. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol. Med. 2003, 9:112-122.
43. Roses A.D. Genetic testing for Alzheimer disease. Practical and ethical issues. Arch. Neurol. 1997, 54:1226-1229.
44. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Vitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2:864-870.
45. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci. 2000, 924:17-25.
46. Sergeant N., Bombois S., Ghestem A., Drobecq H., Kostanjevecki V., Missiaen C., Wattez A., David J.P., Vanmechelen E., Sergheraert C., Delacourte A. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 2003, 85:1581-1591.
47. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106:1489-1499.
48. Sjöbeck M., Haglund M., Englund E. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease-a neuropathological study. Int. J. Geriatr. Psychiatry 2005, 20:919-926.
49. Turner A.J., Fisk L., Nalivaeva N.N. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann. N.Y. Acad. Sci. 2004, 1035:1-20.
50. van Duinen S.G., Castaño E.M., Prelli F., Bots G.T.A.B., Luyendijk W., Frangione B. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:5991-5994.
51. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
52. Wang D.S., Iwata N., Hama E., Saido T.C., Dickson D.W. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 2003, 310:236-241.
53. Webster B., Hansen L., Adame A., Crews L., Torrance M., Thal L., Masliah E. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006, 65:142-151.
54. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999, 398:513-517.
55. Yakoshima K., Akiyama H., McGeer E.G., McGeer P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 2001, 297:97-100.
56. Zhao Z., Xiang Z., Haroutunian V., Buxbaum J.D., Stetka B., Pasinetti G.M. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging 2007, 6:824-830.